Edward Bartlett

Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers

Abstract iNKT cells are emerging as a highly promising immunotherapy platform for the treatment of cancer. To maximise the anti-cancer activity of CAR-iNKT against the blood cancer multiple myeloma we investigated optimal CAR designs and their combination with new iNKT-specific e...